Question explored with the scientific record
Conversation so far
- 1 What are the benefits and risks associated with the shingles vaccine used in the U.K.?
- 2 Why are 2 doses of Shingrix necessary?
- 3 My 2nd dose of Shingrix is scheduled to be given 12 months after the first. Is this normal?
Answered on this page ↓
My 2nd dose of Shingrix is scheduled to be given 12 months after the first. Is this normal?
A 12-month gap between Shingrix doses is not the standard schedule, but it is not harmful either.
The standard schedule is two doses given two to six months apart. That is what the pivotal trials tested. The ZOE-50 and ZOE-70 trials gave two doses and reported 97.2% efficacy in adults 50+ and 89.8% in adults 70+ [3][5]. Protection held at 84.1% efficacy through year eight after the second dose [4].
A 12-month gap is longer than the tested interval. The retrieved evidence does not include any study of a 12-month interval between Shingrix doses. What it does show is that the second dose is what pushes effectiveness up. A Medicare real-world study found one dose gave 56.9% effectiveness against shingles, while two doses gave 70.1% [4]. So the second dose matters, but the exact timing window beyond the tested two-to-six-month range is not covered by these records.
The safety data on the two-dose schedule shows mostly mild-to-moderate reactions, with injection-site reactions, fever, and headache most common [1]. About 44 in 100 people reported some adverse event after a dose in one real-world study [2]. A small Guillain-Barré syndrome signal was noted in one review, about 3 excess cases per million doses within 42 days [4].
The manufacturer, GSK, funded the pivotal trials [1]. No randomized trial comparing a 12-month gap to the standard two-to-six-month gap appears in these records.
My call: the 12-month gap is not the tested schedule, but nothing in the retrieved evidence suggests it is unsafe; the second dose still matters, and you should get it whenever it is offered. Confidence: moderate.
Sources used 5
-
Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIB, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipients
A phase IIIB, non-randomized, open-label study assessing the safety of the adjuvanted recombinant zoster vaccine (RZV) in adults aged 50+ who previously received placebo in ZOE-50/ZOE-70, finding a safety profile consistent with prior trials, with most adverse events being mild-…
DOI: 10.1016/j.vaccine.2020.10.029 -
Safety profile and medium- to long-term protection of the Recombinant Zoster Vaccine (RZV) in a cohort of high-risk patients: real-world data from a General Hospital in Southern Italy, 2021–2025
A prospective real-world study in a Southern Italian hospital evaluated the safety, disease-flare potential, and medium-to-long-term protection against herpes zoster after Recombinant Zoster Vaccine (RZV) in a medically diverse, vulnerable adult population, finding acceptable sa…
DOI: 10.1080/14760584.2025.2589216 -
Evaluating the Immunogenicity, Efficacy, and Effectiveness of Recombinant Zoster Vaccine for Global Public Health Policy
RZV is highly effective against herpes zoster and its complications, with protection lasting at least 10 years across age groups and in immunocompromised populations, but policy decisions require additional considerations such as cost-effectiveness and disease burden data.
DOI: 10.3390/vaccines13030250 -
Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines
This narrative review finds real-world vaccine effectiveness of about 46% for live zoster vaccine and about 85% for recombinant zoster vaccine, with mostly local reactions and a small Guillain-Barré syndrome signal to monitor.
DOI: 10.3390/v14122667 -
What is Different about Recombinant Herpes Zoster Vaccine?
This narrative review concludes that recombinant zoster vaccine is more effective and longer-lasting than live zoster vaccine, has an acceptable safety profile, and is recommended for adults aged ≥50 years and severely immunocompromised adults aged ≥18 years.
DOI: 10.3904/kjm.2024.99.4.180